These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8108907)

  • 21. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
    Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
    Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus disease with atypical presentation in a renal transplant patient: case report.
    Khosravi M; Nobakht A; Nikokar AR
    Exp Clin Transplant; 2006 Jun; 4(1):458-61. PubMed ID: 16827643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
    J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Primary cytomegalovirus infection after combined cadaveric transplantation of the liver and kidney].
    Slavicek J; Puretić Z; Glavas-Boras S; Smalcelj R; Barisić I; Vuković J; Seso-Simić D; Slavicek V; Humar I; Kes P
    Acta Med Croatica; 2003; 57(1):87-90. PubMed ID: 12876872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The emergence of cytomegalovirus resistance to ganciclovir therapy in kidney transplant recipients.
    Nogueira E; Ozaki KS; Tomiyama H; Granato CF; Camara NO; Pacheco-Silva A
    Int Immunopharmacol; 2006 Dec; 6(13-14):2031-7. PubMed ID: 17161359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylaxis for cytomegalovirus in pancreas transplant recipients using intravenous ganciclovir.
    Kohli V; Velosa J; Sterioff S; Munn SR
    Transplant Proc; 1995 Dec; 27(6):2993. PubMed ID: 8539806
    [No Abstract]   [Full Text] [Related]  

  • 27. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients.
    Ozaki KS; Câmara NO; Nogueira E; Pereira MG; Granato C; Melaragno C; Camargo LF; Pacheco-Silva A
    Clin Transplant; 2007; 21(5):675-80. PubMed ID: 17845644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unusual presentation of cytomegalovirus infection in patients after organ transplant.
    Tiple A; Kamar N; Esposito L; Mengelle C; Combelles S; Otal P; Celine Guilbeau-Frugier C; Rostaing L
    Exp Clin Transplant; 2009 Mar; 7(1):45-9. PubMed ID: 19364312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
    Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
    Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful use of oral ganciclovir for the treatment of intrauterine cytomegalovirus infection in a renal allograft recipient.
    Puliyanda DP; Silverman NS; Lehman D; Vo A; Bunnapradist S; Radha RK; Toyoda M; Jordan SC
    Transpl Infect Dis; 2005 Jun; 7(2):71-4. PubMed ID: 16150094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preemptive ganciclovir administration based solely on asymptomatic pulmonary cytomegalovirus infection in allogeneic bone marrow transplant recipients: long-term follow-up.
    Zaia JA; Schmidt GM; Chao NJ; Rizk NW; Nademanee AP; Niland JC; Horak DA; Lee J; Gallez-Hawkins G; Kusnierz-Glaz CR
    Biol Blood Marrow Transplant; 1995 Dec; 1(2):88-93. PubMed ID: 9118297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential cytomegalovirus antigenemia monitoring in kidney transplant patients treated with antilymphocyte antibodies.
    Ozaki KS; Pestana JO; Granato CF; Pacheco-Silva A; Camargo LF
    Transpl Infect Dis; 2004 Jun; 6(2):63-8. PubMed ID: 15522106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N; Holman MJ; Yang HC
    Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytomegalovirus and Epstein-Barr virus-acquired immunity after Sandoglobulin prophylaxis in the pediatric renal transplant population.
    Ham JM; Bunchman TE; Campbell DA; Kershaw DB; Punch JD; Sedman AB; Turcotte JG; Merion RM
    Transplant Proc; 1994 Feb; 26(1):20-1. PubMed ID: 8108942
    [No Abstract]   [Full Text] [Related]  

  • 40. Cytomegalovirus infection in renal transplant recipients.
    Carstens J; Andersen HK; Spencer E; Madsen M
    Transpl Infect Dis; 2006 Dec; 8(4):203-12. PubMed ID: 17116133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.